Zacks Upgrades Derma Sciences to “Outperform” (DSCI)
Derma Sciences (NASDAQ:DSCI) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued on Wednesday, ARN reports. The firm currently has a $12.50 price target on the stock. Zacks‘ price target indicates a potential upside of 15.53% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Sidoti initiated coverage on shares of Derma Sciences in a research note to investors on Thursday, December 19th. They set a “neutral” rating on the stock. Separately, analysts at TheStreet downgraded shares of Derma Sciences to a “sell” rating in a research note to investors on Friday, December 13th. Finally, analysts at Canaccord Genuity cut their price target on shares of Derma Sciences from $20.00 to $19.00 in a research note to investors on Thursday, November 14th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Derma Sciences currently has an average rating of “Hold” and an average target price of $15.75.
Shares of Derma Sciences (NASDAQ:DSCI) remained flat at $10.82 during trading on Wednesday. 37,759 shares of the company’s stock traded hands. Derma Sciences has a 52-week low of $9.93 and a 52-week high of $15.45. The stock has a 50-day moving average of $11.40 and a 200-day moving average of $12.76. The company’s market cap is $187.0 million.
Derma Sciences (NASDAQ:DSCI) last released its earnings data on Wednesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.15. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.96 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Analysts expect that Derma Sciences will post $-1.47 EPS for the current fiscal year.
Derma Sciences, Inc (NASDAQ:DSCI) is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.